

## CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number  
**WO 2003/099793 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 231/12**,  
261/08, 401/04, 413/12, A61K 31/4155, 31/415, 31/42,  
31/422, 31/4439, C07D 231/14, 231/20, 231/22, 401/14,  
403/04, 403/14

(74) Agent: **TAKASHIMA, Hajime**; Fujimura Yamato Seimei  
Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi,  
Osaka 541-0044 (JP).

(21) International Application Number:  
PCT/JP2003/006389

(22) International Filing Date: 22 May 2003 (22.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2002-151405 24 May 2002 (24.05.2002) JP  
2002-287161 30 September 2002 (30.09.2002) JP  
2003-16748 24 January 2003 (24.01.2003) JP

(71) Applicant (for all designated States except US): **TAKEDA  
PHARMACEUTICAL COMPANY LIMITED** [JP/JP];  
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka  
541-0045 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAEKAWA,**  
**Tsuyoshi** [JP/JP]; 2-21, Ioi 1-chome, Ikaruga-cho,  
Ikoma-gun, Nara 636-0124 (JP). **HARA, Ryoma** [JP/JP];  
18-D75-305, Tsukumodai 5-chome, Suita-shi, Osaka  
565-0862 (JP). **ODAKA, Hiroyuki** [JP/JP]; 12-12, Kat-  
suragi 2-chome, Kita-ku, Kobe-shi, Hyogo 651-1223 (JP).  
**KIMURA, Hiroyuki** [JP/JP]; 2-20-808, Ohamanaka-  
machi 1-cho, Sakai-shi, Osaka 590-0975 (JP). **MIZU-**  
**FUNE, Hideya** [JP/JP]; 2-13-603, Yagumodori 2-chome,  
Chuo-ku, Kobe-shi, Hyogo 651-0078 (JP). **FUKATSU,**  
**Kohji** [JP/JP]; 8-4, Tsukushigaoka 5-chome, Kita-ku,  
Kobe-shi, Hyogo 651-1212 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:

10 February 2005

(15) Information about Corrections:


see PCT Gazette No. 06/2005 of 10 February 2005, Sec-  
tion II

Previous Correction:

see PCT Gazette No. 53/2004 of 29 December 2004, Sec-  
tion II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY



(57) Abstract: A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, -O-, -S- and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR<sup>4</sup> (R<sup>4</sup> is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

WO 2003/099793 A1